❌

Reading view

A Workflow for Full Traceability of AI Decisions

arXiv:2511.11275v2 Announce Type: replace Abstract: An ever increasing number of high-stake decisions are made or assisted by automated systems employing brittle artificial intelligence technology. There is a substantial risk that some of these decision induce harm to people, by infringing their well-being or their fundamental human rights. The state-of-the-art in AI systems makes little effort with respect to appropriate documentation of the decision process. This obstructs the ability to trace what went into a decision, which in turn is a prerequisite to any attempt of reconstructing a responsibility chain. Specifically, such traceability is linked to a documentation that will stand up in court when determining the cause of some AI-based decision that inadvertently or intentionally violates the law. This paper takes a radical, yet practical, approach to this problem, by enforcing the documentation of each and every component that goes into the training or inference of an automated decision. As such, it presents the first running workflow supporting the generation of tamper-proof, verifiable and exhaustive traces of AI decisions. In doing so, we expand the DBOM concept into an effective running workflow leveraging confidential computing technology. We demonstrate the inner workings of the workflow in the development of an app to tell poisonous and edible mushrooms apart, meant as a playful example of high-stake decision support.
  •  

The dual immunomodulatory role of B cells in tumorigenesis: mechanisms, microenvironment crosstalk, and therapeutic implications

Front Immunol. 2025 Oct 30;16:1649812. doi: 10.3389/fimmu.2025.1649812. eCollection 2025.

ABSTRACT

B lymphocytes exhibit a multifaceted and context-dependent role in tumor biology, acting as both promoters and suppressors of malignancy through dynamic interactions within the tumor microenvironment (TME). This review synthesizes current evidence on the dual functions of B cells in tumor immunity, highlighting their capacity to orchestrate antitumor responses via antigen presentation, antibody-dependent cytotoxicity, and tertiary lymphoid structure (TLS)-mediated T cell activation, while paradoxically driving immunosuppression through regulatory B cells (Bregs), pro-angiogenic signaling, and immune checkpoint modulation. Key mechanisms include TLS formation, which enhances cytotoxic T cell priming and correlates with improved immunotherapy outcomes, and Breg-mediated secretion of IL-10/TGF-Ξ², which fosters T cell exhaustion and myeloid-derived suppressor cell recruitment. Tumor-type specificity is evident: TLS-rich malignancies like melanoma and Non-Small Cell Lung Cancer (NSCLC) show B cell-driven immune activation, whereas pancreatic and hepatocellular carcinomas demonstrate B cell functional plasticity influenced by metabolic and epigenetic reprogramming. Therapeutically, B cell-targeted strategies-including CD20 antibodies, CAR-T cells, and B cell epitope vaccines-demonstrate efficacy in hematologic and solid tumors, yet face challenges due to subset heterogeneity and sex-specific response disparities. Emerging approaches combine immune checkpoint inhibitors (ICBs) with TLS-inducing agents or exploit B cell-derived biomarkers for personalized therapy. Future directions emphasize deciphering B cell metabolic-niche crosstalk, optimizing combinatorial regimens, and leveraging spatial multiomics to resolve functional heterogeneity. By bridging mechanistic insights with clinical translation, this work underscores B cells as pivotal regulators of tumor immunity and advocates for precision strategies to harness their antitumor potential while mitigating pro-tumor plasticity.

PMID:41246318 | PMC:PMC12611826 | DOI:10.3389/fimmu.2025.1649812

  •  
❌